Skip to search formSkip to main contentSkip to account menu

ALX-0061

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Single-Domain Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
IntroductionThe pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases… 
2014
2014
FRI0329 Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with Alx-0061: Post-Hoc Analysis of Phase I/Ii Data
Background ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety… 
2014
2014
Novartis' lung cancer ALK inhibitor approved
Regulators have backed Janssen’s first-in-class, anti-interleukin-6 (IL-6) Sylvant (siltuximab) for multicentric Castleman’s… 
2013
2013
OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
Background ALX-0061 is a monovalent IL-6R targeting Nanobody. It inhibits signalling via soluble and membrane IL-6R. PK/PD… 
2013
2013
FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab
Background Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which… 
2012
2012
preclinical Development of Alx-0061, an Anti-il-6r Nanobody® for therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License